These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 33573561)

  • 21. Combined analysis of gene expression and genome binding profiles identified potential therapeutic targets of ciclopirox in Ewing sarcoma.
    Yuan B; Ji W; Xia H; Li J
    Mol Med Rep; 2018 Mar; 17(3):4291-4298. PubMed ID: 29328472
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ROS generation attenuates the anti-cancer effect of CPX on cervical cancer cells by inducing autophagy and inhibiting glycophagy.
    Fan H; He Y; Xiang J; Zhou J; Wan X; You J; Du K; Li Y; Cui L; Wang Y; Zhang C; Bu Y; Lei Y
    Redox Biol; 2022 Jul; 53():102339. PubMed ID: 35636017
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ciclopirox olamine promotes the angiogenic response of endothelial cells and mesenchymal stem cells.
    Kremer A; Wußmann M; Herrmann M; Raghunath M; Walles H
    Clin Hemorheol Microcirc; 2019; 73(2):317-328. PubMed ID: 31006674
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Blocking eIF5A modification in cervical cancer cells alters the expression of cancer-related genes and suppresses cell proliferation.
    Mémin E; Hoque M; Jain MR; Heller DS; Li H; Cracchiolo B; Hanauske-Abel HM; Pe'ery T; Mathews MB
    Cancer Res; 2014 Jan; 74(2):552-62. PubMed ID: 24220243
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ciclopirox platinum(IV) conjugates suppress tumors by promoting mitophagy and provoking immune responses.
    Li S; Feng S; Chen Y; Sun B; Zhang N; Zhao Y; Han J; Liu Z; He YQ; Wang Q
    J Inorg Biochem; 2024 Nov; 260():112696. PubMed ID: 39142055
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A density functional theory study on the potential application of Ni and Co doped ZnO nanosheets as a carrier for ciclopirox anticancer drug.
    Taha A; Kadhim MM; Naser ST; Majdi A; Abdullaha SAH; Hachim SK; Abdulwahid Abdulhussain M; Mahdi Rheima A
    Comput Methods Biomech Biomed Engin; 2024 May; 27(6):765-774. PubMed ID: 37781969
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Breast intraductal nanoformulations for treating ductal carcinoma in situ I: Exploring metal-ion complexation to slow ciclopirox release, enhance mammary persistence and efficacy.
    Al-Zubaydi F; Gao D; Kakkar D; Li S; Adler D; Holloway J; Szekely Z; Gu Z; Chan N; Kumar S; Love S; Sinko PJ
    J Control Release; 2020 Jul; 323():71-82. PubMed ID: 32302762
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Repurposing of Metformin for Cancer Therapy: Updated Patent and Literature Review.
    Ahmed ZSO; Golovoy M; Abdullah Y; Ahmed RSI; Dou QP
    Recent Pat Anticancer Drug Discov; 2021; 16(2):161-186. PubMed ID: 34132186
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Breast intraductal nanoformulations for treating ductal carcinoma in situ II: Dose de-escalation using a slow releasing/slow bioconverting prodrug strategy.
    Al-Zubaydi F; Gao D; Kakkar D; Li S; Holloway J; Szekely Z; Chan N; Kumar S; Sabaawy HE; Love S; Sinko PJ
    Drug Deliv Transl Res; 2022 Jan; 12(1):240-256. PubMed ID: 33590464
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The repositioning of the anti-fungal agent ciclopirox olamine as a novel therapeutic agent for the treatment of haematologic malignancy.
    Weir SJ; Patton L; Castle K; Rajewski L; Kasper J; Schimmer AD
    J Clin Pharm Ther; 2011 Apr; 36(2):128-34. PubMed ID: 21366640
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ciclopirox Olamine Exerts Tumor-Suppressor Effects
    Yin J; Che G; Jiang K; Zhou Z; Wu L; Xu M; Liu J; Yan S
    Front Oncol; 2022; 12():791916. PubMed ID: 35251970
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The antitumor activity of the fungicide ciclopirox.
    Zhou H; Shen T; Luo Y; Liu L; Chen W; Xu B; Han X; Pang J; Rivera CA; Huang S
    Int J Cancer; 2010 Nov; 127(10):2467-77. PubMed ID: 20225320
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ciclopirox and Efinaconazole Transungual Permeation, Antifungal Activity, and Proficiency To Induce Resistance in Trichophyton rubrum.
    Monti D; Mazzantini D; Tampucci S; Vecchione A; Celandroni F; Burgalassi S; Ghelardi E
    Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31332076
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The antimycotic ciclopirox olamine induces HIF-1alpha stability, VEGF expression, and angiogenesis.
    Linden T; Katschinski DM; Eckhardt K; Scheid A; Pagel H; Wenger RH
    FASEB J; 2003 Apr; 17(6):761-3. PubMed ID: 12594177
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro transungual permeation of ciclopirox from a hydroxypropyl chitosan-based, water-soluble nail lacquer.
    Monti D; Saccomani L; Chetoni P; Burgalassi S; Saettone MF; Mailland F
    Drug Dev Ind Pharm; 2005 Jan; 31(1):11-7. PubMed ID: 15704853
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ciclopirox: recent nonclinical and clinical data relevant to its use as a topical antimycotic agent.
    Subissi A; Monti D; Togni G; Mailland F
    Drugs; 2010 Nov; 70(16):2133-52. PubMed ID: 20964457
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Repurposing Chloroquine Analogs as an Adjuvant Cancer Therapy.
    Fong W; To KKW
    Recent Pat Anticancer Drug Discov; 2021; 16(2):204-221. PubMed ID: 33413069
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hydrosoluble medicated nail lacquers: in vitro drug permeation and corresponding antimycotic activity.
    Monti D; Saccomani L; Chetoni P; Burgalassi S; Senesi S; Ghelardi E; Mailland F
    Br J Dermatol; 2010 Feb; 162(2):311-7. PubMed ID: 19886884
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Superior efficacy of the antifungal agent ciclopirox olamine over gemcitabine in pancreatic cancer models.
    Mihailidou C; Papakotoulas P; Papavassiliou AG; Karamouzis MV
    Oncotarget; 2018 Feb; 9(12):10360-10374. PubMed ID: 29535812
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ciclopirox Inhibition of eIF5A Hypusination Attenuates Fibroblast Activation and Cardiac Fibrosis.
    Subbaiah KCV; Wu J; Tang WHW; Yao P
    J Cardiovasc Dev Dis; 2023 Jan; 10(2):. PubMed ID: 36826549
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.